A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

Lee Steven Schwartzberg, Francis P. Arena, Bryan J. Bienvenu et al. · Journal of Cancer · 2017

Background: This study was designed to assess the safety and preliminary efficacy of KLTi plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.Methods: In a randomized, open-label study, patients with locally advanced or metastatic pancreatic cancer were randomized 2:1 to receive KLTi plus gemcitabine or gemcitabine monotherapy.Three sequential cohorts were tested at 30 g/day, 50 g/day, and 30 g/day.Gemcitabine was administered at 1000 mg/m 2 on days 1, 8 and 15 of each 28 day cycle.KLTi was administered on days 1-5, 8-12, and 15-19 of each 28 day cycle.Patients received study treatment until disease progression.The primary endpoint was progression-free survival in the ITT population.Safety evaluation was based on patients who received any study treatment.ClinicalTrials.govidentifier NCT00733850.Results: Eighty-five patients were randomized including 41 (28:13) in Cohort 1, 18 (12:6) in Cohort 2, and 26 (17:9) in Cohort 3. Due to a different dose and/or shift in patient populations in Cohort 2 and 3, efficacy data for the 30 gm dose are presented in this manuscript for Cohort 1 alone, and for the combination of Cohort 1+3.The 30 gm KLTi + gemcitabine group had a statistically significant improvement in progression-free survival (PFS) as assessed by blinded independent radiology review in the ITT population, with a median of 112 days, versus 58 days in the gemcitabine group (HR 0.50; 95% CI: 0.27, 0.92), p = 0.0240.The incidence rates of TEAEs, CTCAE Grade 3 or higher TEAEs, and SAEs were similar between the two arms.There were no deaths related to KLTi + gemcitabine treatment.Conclusion: Kanglaite Injection (30 g/day) plus a standard regimen of gemcitabine demonstrated encouraging clinical evidence of anti-neoplastic activity and a well-tolerated safety profile.

Cited by 49 works. doi:10.7150/jca.15407 Open-access PDF

Authors

References